Associated tags: Therapy, CRISPR, MD Anderson Cancer Center, Neutropenia, Novo Nordisk, Bacteria, University, Patent, Patient, Clinical trial, IP, Research, Human
Locations: DENMARK, NEW YORK, UNITED STATES, US, EUROPE
Bone marrow,
FQR,
CRISPR,
Nature Biotechnology,
Safety,
Education,
Pharmacokinetics,
Infection,
Neutropenia,
Survival,
AMR,
Febrile neutropenia,
Gene editing,
Partnership,
Bloodstream infections,
Development,
BMBF,
Escherichia coli,
Research and development,
Patient,
Quinolone antibiotic,
Synthetic biology,
HSCT,
Pharmaceutical industry Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
Key Points:
- Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
- Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
- Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
- SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.
Bone marrow,
FQR,
CRISPR,
Nature Biotechnology,
Safety,
Education,
Pharmacokinetics,
Infection,
Neutropenia,
Survival,
AMR,
Febrile neutropenia,
Gene editing,
Partnership,
Bloodstream infections,
Development,
BMBF,
Escherichia coli,
Research and development,
Patient,
Quinolone antibiotic,
Synthetic biology,
HSCT,
Pharmaceutical industry Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
Key Points:
- Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
- Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
- Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
- SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.
CRISPR,
United States Court of Appeals for the Federal Circuit,
Rockefeller,
Therapy,
Rockefeller University,
European Patent Office,
PTAB,
United States patent law,
AIA,
History,
Leahy–Smith America Invents Act,
Patent,
Hearing,
European Patent Convention,
Court,
Knowledge,
Bacteria,
Cas,
Television The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
Key Points:
- The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
- This ruling has now been overturned in favor of SNIPR following a hearing by the United States Court of Appeals for the Federal Circuit in February 2023.
- a microbiome), demonstrated by the European patent, EP3291679 , titled 'Altering Microbial Populations & Modifying Microbiota' granted by the European Patent Office to SNIPR in 2021.
- Jasper Clube, Co-founder and Chief Patent Counsel of SNIPR Biome, commented, "SNIPR is delighted with this important decision of the Federal Circuit.
CRISPR,
United States Court of Appeals for the Federal Circuit,
Rockefeller,
Therapy,
Rockefeller University,
European Patent Office,
PTAB,
United States patent law,
AIA,
History,
Leahy–Smith America Invents Act,
Patent,
Hearing,
European Patent Convention,
Court,
Knowledge,
Bacteria,
Cas,
Television The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
Key Points:
- The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
- This ruling has now been overturned in favor of SNIPR following a hearing by the United States Court of Appeals for the Federal Circuit in February 2023.
- a microbiome), demonstrated by the European patent, EP3291679 , titled 'Altering Microbial Populations & Modifying Microbiota' granted by the European Patent Office to SNIPR in 2021.
- Jasper Clube, Co-founder and Chief Patent Counsel of SNIPR Biome, commented, "SNIPR is delighted with this important decision of the Federal Circuit.
Retrieved on:
Thursday, December 22, 2022
Patent issuance adds to SNIPR's extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe
Key Points:
- Patent issuance adds to SNIPR's extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe
COPENHAGEN, Denmark, Dec. 22, 2022 /PRNewswire/ -- SNIPR Biome ApS ("SNIPR" or "the Company"), the company pioneering CRISPR-based microbial gene therapy, announces today the grant of a new patent by the US Patent and Trademark Office (USPTO).
- In August 2022, SNIPR was awarded patent number US11,400,110 which covers lytic phage armed with CRISPR gene editing systems.
- Dr Christian Grøndahl, Co-founder and CEO of SNIPR Biome, commented: "This expansion of our patent estate strengthens our already extensive intellectual property portfolio covering the use of CRISPR/Cas to edit prokaryotes.
- SNIPR Biome is a leader in this transformational area of science, with a clinical trial underway, strong IP, and a diverse and experienced team.
Retrieved on:
Thursday, December 22, 2022
Patent issuance adds to SNIPR's extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe
Key Points:
- Patent issuance adds to SNIPR's extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe
COPENHAGEN, Denmark, Dec. 22, 2022 /PRNewswire/ -- SNIPR Biome ApS ("SNIPR" or "the Company"), the company pioneering CRISPR-based microbial gene therapy, announces today the grant of a new patent by the US Patent and Trademark Office (USPTO).
- In August 2022, SNIPR was awarded patent number US11,400,110 which covers lytic phage armed with CRISPR gene editing systems.
- Dr Christian Grøndahl, Co-founder and CEO of SNIPR Biome, commented: "This expansion of our patent estate strengthens our already extensive intellectual property portfolio covering the use of CRISPR/Cas to edit prokaryotes.
- SNIPR Biome is a leader in this transformational area of science, with a clinical trial underway, strong IP, and a diverse and experienced team.
Lymphatic system,
Human,
Technology,
LinkedIn,
Research,
Clinical trial,
CEO,
Twitter,
Patent,
Infection,
Bacteria,
Method,
IP,
Patient,
Company,
Pharmaceutical industry,
Vaccine,
CRISPR SNIPR has developed a technology platform that uses CRISPR/Cas to precisely target and edit prokaryotes, such as bacteria.
Key Points:
- SNIPR has developed a technology platform that uses CRISPR/Cas to precisely target and edit prokaryotes, such as bacteria.
- The Company has an extensive patent portfolio which contains more than 20 granted patents in the US and Europe.
- SNIPR is committed to enabling and fueling the development of innovative therapies using the technologies covered by its patent estate.
- For non-commercial academic and non-profit use, no written license to SNIPRs CRISPR tools, methods, or other intellectual property is necessary.
Lymphatic system,
Human,
Technology,
LinkedIn,
Research,
Clinical trial,
CEO,
Twitter,
Patent,
Infection,
Bacteria,
Method,
IP,
Patient,
Company,
Pharmaceutical industry,
Vaccine,
CRISPR SNIPR has developed a technology platform that uses CRISPR/Cas to precisely target and edit prokaryotes, such as bacteria.
Key Points:
- SNIPR has developed a technology platform that uses CRISPR/Cas to precisely target and edit prokaryotes, such as bacteria.
- The Company has an extensive patent portfolio which contains more than 20 granted patents in the US and Europe.
- SNIPR is committed to enabling and fueling the development of innovative therapies using the technologies covered by its patent estate.
- For non-commercial academic and non-profit use, no written license to SNIPRs CRISPR tools, methods, or other intellectual property is necessary.
Biomedical Advanced Research and Development Authority,
Education,
BARDA,
NIH,
ASPR,
Bacteria,
Bill,
Bill & Melinda Gates Foundation,
NIAID,
Boston University,
Twitter,
Human,
United States patent law,
CEO,
Lymphatic system,
Development,
National Institute,
Partnership,
IP,
Cas9,
Office of Inspector General, U.S. Department of Health and Human Services,
Infection,
Patent,
Federal Ministry of Health (Germany),
CRISPR,
National Institute of Allergy and Infectious Diseases,
Social,
Assistant,
Cas3,
Clinical trial,
Human services,
Technology,
FDA,
Boston University School of Law,
Patient,
LinkedIn,
BMBF,
Annual report,
Therapy,
2020–2021 Thai protests,
Office of the Assistant Secretary for Preparedness and Response,
Communication,
USPTO,
Cas,
Pharmaceutical industry,
Research,
Wellcome SNIPR Biome is the first company to orally dose humans with a CRISPR therapeutic and SNIPR001 has been granted Fast-Track designation by the FDA.
Key Points:
- SNIPR Biome is the first company to orally dose humans with a CRISPR therapeutic and SNIPR001 has been granted Fast-Track designation by the FDA.
- The new patent covers lytic phage armed with CRISPR gene editing systems.
- CRISPR and phage lysis of target bacteria is a potent combination for therapeutics, and the patent includes the use of any CRISPR system, for example, Cas9, Cas3, or any other Cas nuclease.
- The new patent adds to the companys extensive patent estate protecting this technology, including granted patent number US10,920,222 with a fundamental scope protecting fast and durable action of CRISPR targeting in E coli.
